Jade Biosciences, Inc. (JBIO)
About Jade Biosciences, Inc.
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$127.4M
- Total assets
- $349.8M
- Market cap
- $1.2B
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $113.5M
- Operating income
- -$113.5M
- Income tax
- $58.0K
- Net income
- -$127.4M
- EPS (basic)
- $-3.19
- EPS (diluted)
- $-3.19
Balance sheet
- Total assets
- $349.8M
- Current assets
- $348.8M
- Total liabilities
- $17.3M
- Current liabilities
- $16.5M
- Shareholders’ equity
- $332.5M
Cash flow
- Operating cash flow
- -$94.7M
- Investing cash flow
- -$247.0M
- Financing cash flow
- $360.8M
- Net cash flow
- $19.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.2B
- EPS (diluted)
- $-3.19
- Shares outstanding
- 50.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 29, 2025
Jade Biosciences, Inc. (JBIO) Stock Price
- Reported a net loss of $127.4M.
- Trading 25% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Jade Biosciences, Inc..
Write a review
News about Jade Biosciences, Inc.
News & sentiment via Polygon.io
Jade Biosciences, Inc.: frequently asked questions
Is Jade Biosciences, Inc. an American company?
Jade Biosciences, Inc. is a US-based company headquartered in Waltham, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Jade Biosciences, Inc. headquartered?
Jade Biosciences, Inc. is headquartered in Waltham, Massachusetts, United States.
Is Jade Biosciences, Inc. publicly traded?
Yes — Jade Biosciences, Inc. is a publicly traded company. Its stock trades under the ticker symbol JBIO on the NASDAQ.
What does Jade Biosciences, Inc. do?
Jade Biosciences, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
